The DTNB Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population generated by disruption of the DTNB gene in NCI-H1299 cells. This pool of knockout cells provides a versatile loss-of-function model without the need for clonal isolation, suitable for studying dystrobrevin beta function in a heterogeneous cell background.
NCI-H1299 is a human lung adenocarcinoma cell line derived from a lymph node metastasis, widely used as a model for non-small cell lung cancer (NSCLC). These cells are p53-deficient and of epithelial origin, displaying robust proliferation and invasive potential. They are extensively characterized in cancer cell biology for migration, invasion, and metastasis research.
DTNB encodes dystrobrevin beta, a scaffolding protein within the dystrophin-glycoprotein complex (DGC). It links the actin cytoskeleton to the extracellular matrix through interactions with dystrophin (DMD), utrophin (UTRN), syntrophins (SNTA1, SNTB1), sarcoglycans, and dystroglycan (DAG1). DTNB is transcriptionally regulated by PAX3/PAX7 and MEF2C, and is responsive to integrin-mediated signaling and mechanical stress. Downstream, it influences the localization of neuronal nitric oxide synthase (nNOS) and modulates MAPK pathway activity, contributing to membrane stability, adhesion signaling, and force transduction.
In NCI-H1299 cells, DTNB disruption is expected to impair DGC assembly and function, potentially altering cell adhesion, cytoskeletal organization, and migration. This model enables the investigation of how dystrophin-associated proteins contribute to lung cancer mechanotransduction and metastatic behavior, shedding light on the molecular mechanisms by which tumor cells interact with the extracellular matrix and respond to mechanical cues.
Researchers can employ these cells in Western blotting and immunofluorescence to confirm DTNB loss and assess DGC components. Functional studies may include migration and invasion assays (Transwell, wound healing), adhesion assays, and phospho-signaling analysis by flow cytometry or western blotting. Transcriptomic profiling via RNA-seq can reveal broader gene expression changes. These applications make the product ideal for studying cancer cell migration, mechanobiology, and drug response. For further information, please contact Ascent Research.
